ABSORV at Long Term in Daily Practice Lesions

absorv abbottThis work reports one year outcomes of the BVS Expand registry. Multiple studies have shown the safety and feasibility of the everolimus eluting bioresorbable scaffold ABSORB (Abbott Vascular, Santa Clara, California), but medium and long term data are limited and only on simple lesions.

 

This is a prospective single-center registry assessing ABSORB performance in lesions representative of the daily practice, such as:

  • Calcified lesions
  • Total occlusions
  • Long lesions
  • Small vessels

 

Inclusion criteria were patients presenting with non ST elevation MI, stable or unstable angina or silent ischemia caused by de novo stenotic lesions in native coronary arteries.

 

Primary end point were major adverse cardiovascular events (MACE) defined as a composite of:

  • Cardiac death
  • Acute myocardial infarction
  • Target vessel revascularization

 

Between September 2012 and January 2015, 249 patients with 335 lesions were included. The mean number of scaffolds per patient was 1.79 ± 1.15. Invasive imaging was used for scaffold implantation in 39% of patients.

 

Mean follow up was 622 days (376 a 734). Using Kaplan-Meier, at 18 months:

  • MACE rate was 6.8%.
  • Cardiac death rate was 1.8%.
  • AMI rate was 5.2%.
  • Target lesion revascularization rate was 4.0%. Scaffold definite thrombosis rate was 1.9%.

 

Conclusion

In complex patients and lesions, the ABSORB resorbable scaffold showed acceptable performance at long term. There were no cases of early thrombosis.

 

Original Title: Mid- to Long-Term Clinical Outcomes of Patients Treated With the Everolimus-Eluting Bioresorbable Vascular Scaffold. The BVS Expand Registry.

Reference: Cordula M. Felix et al. J Am Coll Cardiol Intv. 2016;9(16):1652-1663.

 

We value your opinion. You are more than welcome to leave your thoughts, comments, questions or suggestions here below.

More articles by this author

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | FLAVOUR II: Angiography-Derived FFR-Guided vs. IVUS-Guided PCI

Physiological assessment is effective when it comes to decision-making for percutaneous coronary intervention (PCI). However, despite the available evidence, its use remains limited. AngioFFR...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...